Kkr & Co. Inc.
—- Market cap
- $96.70B
- Debt
- +$328.51B
- Cash
- —
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 23% equity / 77% debt
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 ·
Decision snapshot: KKR stock price vs IDYA: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at IDYA's multiple
Needs IDYA P/E.
Implied fair value · at KKR's multiple
Needs EPS (TTM) is negative, KKR P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: KKR FY 2025 (ended Dec 31, 2025) · IDYA FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 23% equity / 77% debt
Capital structure 98% equity / 2% debt · EV / Revenue 15.05x
KKR carries the larger enterprise value at $425.21B against $3.29B; IDYA trades on the lower EV / Revenue multiple (15.05x vs 21.85x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
KKR & CO. INC. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
IDEAYA Biosciences, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
10.63x
0.08x
Net debt / EBITDA
Leverage against operating earnings
—
4.97x
Cash and equivalents
Liquid reserves on the balance sheet
—
$639.39M
Total debt
Interest-bearing obligations outstanding
$328.51B
$84.13M
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
BlackRock, Inc.
KKR vs BLK
Blackstone Inc.
KKR vs BX
Apollo Global Management, Inc.
KKR vs APO
Carlyle Group Inc.
KKR vs CG
Ares Management Corp
KKR vs ARES
Zentalis Pharmaceuticals, Inc.
KKR vs ZNTL
Blueprint Medicines Corp
KKR vs BPMC
Jazz Pharmaceuticals plc
KKR vs JAZZ
Sarepta Therapeutics, Inc.
KKR vs SRPT
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.